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Dear Editor, 
Meta-analyses combine data and summarize the findings of several clinical trials or of research 
studies. In the last years the utilization of this statistical approach has increased both in clinical 
and in research setting.1-3 However, the interpretation of their data could vary among authors. In 
the last issue of Panminerva Medica we have read with interest the article by Hu et al, evaluating 
the association between PON1 (paraoxonase) L55M polymorphism and the presence of a cancer. 
Since the authors found an overall odds ratio (OR) of 1.21 (95% confidence interval [CI]: 1.04 -
1.40) concluded that this polymorphism might increase the risk of cancer in general. In Table III 
the authors reported the data for neoplasm included by each study (prostate, breast, ovarian, lung 
and colorectal). Only in case of breast cancer the CI was > 1.4 Moreover, in this setting was 
included the study by Hussein et al, with an odds ratio (OR) = 6.35 and a large CI (3.88-10.40).5 
Hence, this could have unbalanced the overall result, considering also the results reported in 
Figure 2.4  CIs provide upper and lower limits that capture the range of values around the true but 
unknown population value. The 95% CI is most commonly used and corresponds with the 
typical 5% significance level used in hypothesis tests. It is accepted that CIs of continuous 
measures that include 0 represent non-significant results. CIs of ORs and relative risk that 
include 1.0 represent non-significant results.6 
On the basis of these considerations we think that the conclusion of this meta-analysis should be 
that it has shown an association between PON1 (paraoxonase) L55M polymorphism and breast 
cancer and not cancer in general. 
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